Mrna patent number. The invention provides preparative purification of RNA (e.

Mrna patent number Additionally, there are several pending patent lawsuits related to key components of mRNA platform technologies, with strong implications for follow . Publisher’s note. In our final post in this series on mRNA IP and the competitive landscape through one year of the COVID-19 pandemic, we provide an analysis of the current landscape and offer conclusions. 2015; 25, R526–R532. Additionally, there are several pending patent lawsuits related to key components of mRNA platform technologies, with strong implications for follow A network analysis of COVID-19 mRNA vaccine patents Nat Biotechnol. 2023 Sep;41(9):1193-1199. During this time period, two of the five The global mRNA vaccine patent landscape. Malone The present invention describes methods of removing DNA from an RNA transcript during the mRNA production process. Although mRNA vaccines were Large pharmaceutical companies that lagged behind in the race for the vaccine are now investing heavily in mRNA, including Sanofi, which bought Translate Bio for The present disclosure is directed to methods of immunization and methods for generating antibodies using compositions comprising cationic lipids and polynucleotide molecules, such as polyribonucleotide molecules, e. LNP constructs include novel ionizable lipid. 2022. Grant share is based on the ratio of number of grants to total number of patents. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, Patent numbers Grant date Comment Plaintiff(s) Defendant(s) Cause of action Case number Court name Accused products Patent litigation filed or closed in Q4 2022 NO PATENT RIGHTS TRANSFERRED THIS QUARTER BIONTECH SANOFI STRAW MAN* Opposition procedure at the EPO EP3590949 Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof On 19 December 2023, the Federal Patent Court declared the German part of the European patent EP 1 857 122 B1 (please see here) of CureVac of Tübingen invalid following an action for revocation brought by BioNTech from Mainz. The DNA can be removed by adding either free DNase or a resin containing immobilized DNase to the product, and While the protein expression of non-replicating mRNA depends on the number of transcripts that are successfully delivered, saRNA produces a large amount of antigen even at low doses because of its self-replicating characteristics [43]. Authors Mengru Lyu # GB202101114D0 - PROCESS FOR mRNA PURIFICATION - Google Patents PROCESS FOR mRNA PURIFICATION Info Publication number GB202101114D0. For example, TI=(safety belt). That statement was updated earlier this year, when the In addition, the resulting protein was tested to determine if it was active and functioned properly. GSK says it is owed a por­tion of Pfiz­er and BioN­Tech’s Covid-19 vac­cine sales in the lat­est patent suit filed against the Comir­naty part­ners. reassignment MODERNATX, INC. 1080/21645515. As the number of granted patents in the mRNA field increases, and as new valuable technologies enter the market, we would expect to see more litigation in the future. From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. From a total The patent landscape for RNA-based therapeutics is not closed or static – to the contrary, it continues to expand. 4: The COVID-19 pandemic may have opened the door to fundamentally transforming the drug development space, and Moderna’s patent pledge may serve As mRNA-based drugs have expanded and their indications have broadened, more patents for mRNA innovations have emerged. PATENT NO: 9597413: APP PUB NO: 20140294939A1: SERIAL NO: 14308554: DOCKET NO : 0 Status Updates Download: Stats. 114 EUR. In the pan-European dispute between Moderna and BioNTech over mRNA patents, the patent holder Moderna has now suffered a defeat at the European Patent Office. priority date . The global patent landscape for mRNA therapy has not yet been analyzed, indicating a research gap in need of filling, from new technology to productization. Biotechnology Coronavirus impact on patent European Patent Office Print. Rankings More Top / Flop Rankings More Top / Flop Currency / The current landscape for preparative chromatographic RNA purification uses reversed phase HPLC, but this technique presents many issues with process scale up and ion exchange for preparative purification has only been used for short RNAs. (b) mRNA vaccine patent families by publication year in the top five patents to mRNA RiboTherapeutics, which then sublicensed them to its affiliate CellScript. , Transfection of dendritic cells with RNA induces CD4- and COB-mediated T The quarterly report for the Q2 2023 Therapeutic mRNA Patent Monitor will be released next July. The patent also highlights the use of cutting-edge RNA technology, including linear and circular mRNA, both replicating and non-replicating, to produce the anti-gen. Google has not performed a legal analysis and makes no The present invention in general relates to a combination of mRNA molecules encoding functional immunostimulatory proteins and a PD-1 pathway inhibitor. 1), mRNA was first discovered by pioneering researches in 1961. 1038/s41587-023-01925-2. successfully a relatively low number of patent publications. Both Moderna and BioNTech, as well INT mRNA mRNA-4157 (V940) is a customizable individualized neoantigen therapy encoding up to 34 neoantigens Targeting of neoantigens by T-cells has been demonstrated to drive antitumor responses1 The modified mRNA platform was implemented for the COVID-19 vaccine (mRNA-1273), demonstrating its utility and adaptability2 The invention relates to mRNA comprising lipid nanoparticles and their medical uses. Patent topics related to mRNA therapeutics largely focus on drug research, disease mechanism, immune research, and signaling molecules research. The complaint alleges that Moderna infringed a number of Arbutus-owned patents (i. ) Withdrawn Application number EP93911170A Other languages German (de) French (fr) Other versions A comprehensive analysis of antibody (Ab) and T cell responses to two doses of BNT162b2 mRNA vaccination was performed in 103 HDR, including 75 SARS-CoV-2 naive and 28 experienced patients, and in 106 healthy controls (HC) not undergoing HD, including 40 SARS-CoV-2 naive and 66 experienced subjects. Consensus. Authors Mario Gaviria 1 , Burcu Kilic 2 Affiliations 1 Department of Chemistry, University of Michigan, Ann Importantly, from an intellectual property perspective, this means that a number of patents relevant to mRNA vaccine platforms pre-date the COVID-19 pandemic. (2005 and 2008) on the incorporation of modified nucleoside into mRNA to increase stability and to ablate Application number US11/990,646 Other versions US20090286852A1 (en Inventor Katalin Kariko Drew Weissman Current Assignee (The listed assignees may be inaccurate. 특히, 이는 CD40L, CD70 Patent information Numbers, dates, assignees, title, abstract, claims, hyperlink to updated online database (legal status, original documents etc. 2095837 Journal: Human Vaccines & Immunotherapeutics, 2022, № 6 Publisher The first patent family identified was published in 1990. If you have anyfurther questions, ask your doctor, pharmacist or nurse. Who We’ve seen a post online claiming that Bill Gates and Microsoft have a patent, numbered 060606, for a microchip that would be inserted into people’s bodies, and would monitor their activity in return for cryptocurrency. Last month, the patent battle between COVID-19 mRNA vaccine manufacturers continued with BioNTech/Pfizer filing a strong defense and counter-claim to Moderna’s allegations of patent infringement. A 2023 report by the European Patent Office showed an increase of around 400% in the number of international patent families relating to mRNA vaccine technologies between 2015 and 2021. [65] [66] Research into using lipids to deliver siRNA to cells became a foundation for similar research into using lipids to deliver mRNA. inter partes review proceedings (IPRs), two total European oppositions, as we previously discussed) or major changes to its already sizable patent portfolio. Indeed, the increase in patent publications mainly corresponds to an increase in the number of assignees rather than an increase in the number of patent However, the landscape of mRNA patents is getting complicated and dense, with an accumulation of partially overlapping patent rights that require multiple rights holders’ permission for use and commercialization. In a recent financial statement, Moderna suggested that it relies to a certain extent on trade secrets, know-how, and technology, which are not protected by It is also worth noting the significant number of patents granted to SANOFI in the last quarter, including some that were filed by TRANSLATE BIO. Biol. 4. Patents on mRNA vaccination against corona and COVID-19. Several determinants of Key Moderna mRNA patent invalidated by EPO. RNA molecules Different types exist including mRNA molecules that carry the genetic information for protein synthesis. You may need to read it again. Grant share is based on the ratio of number of grants to total number of patents. 8, Table 1) to evaluate protein activity. The AGS Therapeutics: Pioneering Microalgae-Based Drug Delivery for Therapeutic mRNA AGS therapeutic, a French newcomer to follow. Use TI= to search in the title, AB= for the abstract, CL= for the claims, or TAC= for all three. This statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s development of its COVID-19 The mRNA is formulated in a lipid nanoparticle comprising 15-20 mol% neutral lipid, 35-45 mol% cholesterol, 0. 6. Here, the figure released for 2021 was shown to be decreased compared to that of the previous year, which may be related to (Reuters) -Moderna said on Friday the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer and BioNTech. Keep this leaflet. This Figure 4 b shows the number of mRNA patent documents published annually. In eukaryotes, these mRNA molecules are transcribed from the An increased level of translation of a selected mRNA molecule is effected by coupling specific nucleotide sequences at the 5'- and 3' -ends of a nucleic acid molecule transcribable to or which itself is the mRNA molecule. Mar 21, 2017 Grant Date; Oct 2, 2014 app pub date; Jun 18, 2014 filing date; Jun 8, 2011. As Like Moderna, BioNTech has reportedly in-licensed foundational mRNA patents based on advancements made by Drs. Since then, there has been a steady growth in the number of inventions; in 1990, approximately 25 patents were filed compared to around 350 in 2021. 60%. The method embodies procedures for obtaining an in vitro transcription product, and removing any DNA from the product. Publication number US10653767B2 . , mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes, Cancer Gene Therapy, 2007, 14, pp. Description. Assignors: HIMANSU, Sunny, CIARAMELLA, GIUSEPPE 2019 mRNA-1273 Vx Patent Landscape. •Includes 3 vaccines based on mRNA technology: Moderna’s Elasomeran/mRNA-1273, Pfizer/BioNtech’sTozinameran/BNT162b2, and CureVAC ‘s Zorecimeran/CVnCoV- (not approved). , mRNA, which code for immunogens (e. Ther. This European Patent Office Prior art keywords ala leu gin ser thr Prior art date 1992-05-08 Legal status (The legal status is an assumption and is not a legal conclusion. ) Active Application number US17/556,974 Other versions US20220105201A1 (en Inventor mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Real-world observations through the CDC v-safe tracking program have not uncovered unusual numbers of adverse events or Core regions for mRNA(LNP) patent distribution include the United States, Patent Corporation Treaty (PCT), China, Australia, and Canada, accounting for nearly 65% of the distribution. e. Epub 2022 Jul 7. Includes 3 vaccines based on mRNA technology: Moderna’s Elasomeran/mRNA-1273, Pfizer/BioNtech’s The new patent insight report summarises the results of patent analyses related to mRNA-based vaccines which were carried out jointly by subject-matter specialists and patent knowledge experts at the EPO, using To determine who has played a pivotal role in mRNA patents, we identified the top 15 inventors by number of patent applications (Table 1). Since 2021, the number of published patents has increased in the United States, PCT, and China, while Australia and Canada show a decreasing trend. Company calendar Indexes Europe America Asia More Indexes My Watchlist My lists. In the case of mRNA replacement therapy (MRT) employing hEPO mRNA, hematocrit changes were monitored over a ten day period for five different lipid nanoparticle formulations (FIG. All claims expressed in this article Importantly, from an intellectual property perspective, this means that a number of patents relevant to mRNA vaccine platforms pre-date the COVID-19 pandemic. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list. But it is also not the first time we have seen mediation being encouraged in patent cases in China. •Includes patents on underlying technologies. US 10,975,369. Adam Houldsworth. Karik BioNTech has reportedly entered into a number of collaborations including with Pfizer (July Vaccines of the mRNA type - such as Pfizer and Moderna - are a new breed and only a small number of people understand how to make them. In Force. Taken together, we uncovered 165 motifs with coherent effects, including 47 unique CNV events, 70 mRNA probes, and 75 lncRNA probes (Table S5). 21 November 2023 by Konstanze Richter. Meade J found CureVac’s patents, relating to split poly(A) tails in mRNA, invalid for obviousness and insufficiency due to (i) lack of plausibility and (ii) because the purported technical effect does not in fact exist over substantially the whole scope Number of Analysts. Mrna constructs for treating cystic fibrosis via Furthermore, the German company CureVac, an early mRNA pioneer whose mRNA vaccine stalled after showing just 47% efficacy against COVID-19 in a late-stage trial (2022), protects several inventions that the company considers critical to the design and development of BioNTech’s mRNA COVID-19 vaccine. 4 However, it was not until 1990 when Wolff et al. ) Active Application number Patent information number 10702600 (US patent registration), the innovation was titled ‘Beta coronavirus in RNA vaccine’. mRNA was discovered in 1961 Cobb M. The methods are designed for significantly larger mRNAs Fig. Along the way, we have accumulated a broad collection of patents, with several hundred additional pending patent applications. The Opposition Division has revoked one of the patents-in-suit. Initial challenges associated with introducing mRNA molecules into cells such as the instability of mRNA molecules and immune responses have been successfully met using for example chemically modified nucleotides (WO 2011/012316; EP patent application number 18 15 6466. According to a 2020 review of patent filings related to mRNA vaccines, “The patent-filing activity grew Nous voudrions effectuer une description ici mais le site que vous consultez ne nous en laisse pas la possibilité. Inducing immune response against hiv using mrna compositions In order to characterize the patent landscape of mRNA vaccines, this study collated mRNA vaccine-related applications that have been registered since 1962. patent number 10,933,127 [Application Number 16/880,829] was granted by the patent office on 2021-03-02 for betacoronavirus mrna vaccine. The general trend across all Reversed phase-High Performance (High Pressure) Liquid Chromatography (RP-HPLC) and Size Exclusion Chromatography (SEC) methods have been developed for monitoring structural and size heterogeneity as well as stability of large RNA transcripts, including lengths of up to at least 10,000 nucleotides. https://doi. Register now Subscribe to unlock unlimited access. Conflict of interest . Comprises patent information on 13 approved or late-stage COVID-19 vaccines. To read more. In July 2021, the China National Intellectual Property Administration (CNIPA) was empowered to hear patent The post-COVID mRNA patent wars. patents relevant to our mRNA-1273 vaccine against COVID-19 is available here. This patent grant is currently assigned to ModernaTX, Inc. 3A GB202101114A GB202101114D0 GB 202101114 D0 GB202101114 D0 GB 202101114D0 GB 202101114 A GB202101114 A GB 202101114A GB 202101114 D0 Patent number. Justia Patents US Patent for Zika virus mRNA vaccines Patent (Patent # 11,207,398) Zika virus mRNA vaccines . Average target price. In this post we provide a 2021 The specific US government patent in question — US patent number 10,960,070, better known as the ’070 patent — relates to how the spike protein is stabilised in the vaccine, a technique that was developed by the NIH’s Vaccine Research Center. ) University of Pennsylvania Penn Original Assignee University of Pennsylvania Penn Encapsulating the mRNA molecule in lipid nanoparticles was a critical breakthrough for producing viable mRNA vaccines, solving a number of key technical barriers in delivering the mRNA molecule into the host cell. (a) the number of mRNA vaccine patents invented by publication year since 1962. COVID-19 pandemic has had a substantial impact on global health The NIH were granted patents in the United States and Europe, among other venues, with claims related to a recombinant coronavirus protein comprising one or two proline substitutions near the A patent landscape of assignees claiming an mRNA vaccine was generated from the collected set of documents. , U. Register for limited access. US8519110B2 US12/996,243 US99624309A US8519110B2 US 8519110 B2 US8519110 B2 US 8519110B2 US 99624309 A US99624309 A US 99624309A US 8519110 B2 US8519110 B2 US 8519110B2 Authority US United States Prior There has been no change in the number of mRNA-based IPRs and oppositions that Moderna has filed (remaining at four total U. Stimulated by the COVID-19 pandemic, the annual number of The current landscape for preparative chromatographic RNA purification uses reversed phase HPLC, but this technique presents many issues with process scale up and ion exchange for preparative purification has only been used for short RNAs. Patent Nos. Who discovered messenger RNA? Curr. Along the way, we have accumulated a broad collection of mrna rna protein hcov vaccine Prior art date 2015-10-22 Legal status (The legal status is an assumption and is not a legal conclusion. 802-814. US20180105551A1 US15/788,742 US201715788742A US2018105551A1 US 20180105551 A1 US20180105551 A1 US 20180105551A1 US 201715788742 A US201715788742 A US 201715788742A US The APC was funded by The Mexican Council of Science and Technology (CONACyT), grant number SEP-CONACyT-CB-286421. 21 November 2023. Below is a brief overview of the key disputes: According to the analysis of the number of mRNA vaccine patents in the region where the assignee was located, the United States was shown to be the global leader with 688 patent families, followed by China (336) and Germany (232), which accounted for 72% of the global total. ) & Segmentation by application (Prophylactic vaccine, Therapeutic vaccine, Therapeutic drugs), and by pathology (infectious disease, oncology, As of 2019, this trend continues. This video can not be played mrna Prior art date 1989-03-21 Legal status (The legal status is an assumption and is not a legal conclusion. This trend is reflected in Figure 1 of the report COVID-19 mRNA Vaccine (nucleoside modified) tozinameran Read all of this leaflet carefully before you receive this vaccine because it contains important information for you. Below is our non-exhaustive list. , anion) exchange chromatography that allows According to GlobalData’s company profile on Arcturus Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Search by Cooperative Patent Classifications (CPCs): These are commonly used to represent ideas in place of keywords, U. US10653767B2 US16 2018-09-14 Priority to US16/131,793 priority Critical patent/US10653767B2/en 2019-02-21 Assigned to MODERNATX, INC. ) Patent segmentation Technological segmentation (mRNA design, modifications, carrier, etc. The nucleotide sequence at the 5'-end is effective to increase the rate of translation initiation of the mRNA molecule in a cell while the nucleotide sequence at Between 2011 and 2019, the number of mRNA-related patents worldwide increased from 46 to 177 each year. The patent search undertaken for this report looked at related patent Since April 2021, increasing number of cases of myocarditis and pericarditis have been reported in the United States in about 13 per 1 Besides making mRNA, the Marburg facility also performs the step of combining mRNA with lipids to • Patents directed at an mRNA vaccine or RNA generally • Patents directed at Lipids/NP + mRNA • Patents specifically directed at pharmaceutical compositions involving lipid NP + mRNA. Estimate revisions Quarterly revenue - Rate of surprise. S. Arcturus Therapeutics's grant share as of July 2024 was 33%. These mRNAs and lncRNAs map to 56 unique human genes. Last Close Price. This vaccine technology platform uses mRNA From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. R. 1038/s41587-021-00912-9. This means that the patent is ab initio invalid for the German territory, with retroactive effect from the outset. A detailed analysis of the patent litigation that started in 2022, when many countries began to treat COVID-19 as an endemic virus, can be found in our article, ‘The role of patents in protecting investment in mRNA technology’, that was just published in the Bio-Science Law Review. Publication trend of mRNA vaccine patents. Disease type Number of patent applications Proliferative disorders Publication number US10933127B2 . . The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Methods for large-scale purification of mRNA that includes, at least, a step of centrifuging an mRNA suspension in a centrifuge The number of patents filed relating to use of mRNA as a vaccine for both infectious diseases and cancer has increased dramatically over the five years to 2020. 본 발명은 일반적으로 기능적 면역자극 단백질을 암호화하는 mRNA 분자 및 CTLA4 경로 억제제의 조합에 관한 것이다. The grantee listed for this patent is ModernaTX, Inc. SAN DIEGO – TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids such as DNA and RNA, announced today that the United States Patent and Trademark Office has issued two new patents to the company. , anion) exchange chromatography that allows 2019-09-13 Priority to US17/276,112 priority Critical patent/US20220054653A1/en 2021-03-19 Assigned to MODERNATX, INC. 2095837. Although the clinical applications of saRNAs in preventing infectious diseases are promising, their utilization in cancer vaccines Published patents and patent applications are an important source of technical and legal information. However, the judgement is not yet US8519110B2 - mRNA cap analogs - Google Patents mRNA cap analogs Download PDF Info Publication number US8519110B2 . •Patent status worldwide. The description mentioned in the patent is that the vaccine is a lipid nanoparticle (LNP) encapsulated mRNA. As we highlighted in our previous article, numerous companies Brief history of mRNA drug development. Moderna's grant share as of July 2024 was 23%. Spread / Average Target +67. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed. In mrna protein lipid compositions lipid nanoparticle Prior art date 2011-06-08 Legal status (The legal status is an assumption and is not a legal conclusion. According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). , 16(11):1833-40). Felgner Jon A. WATCH: Pfizer v Oxford v Moderna – three Covid-19 vaccines The specific US government patent in question — US patent number 10,960,070, better known as the ’070 patent — relates to how the spike protein is stabilised in the vaccine, a technique that The relationship between the number of patent documents and their publication year in the top seven jurisdictions of mRNA vaccine patents is shown in Figure 1 c. GB202101114D0 GBGB2101114. Assignors: MARTINI, PAOLO, CAO, JINGSONG, PRESNYAK, Vladimir 2022-02-24 Publication of US20220054653A1 Additionally, the antigen is linked to an adjuvant using recombinant technology, further boosting its potency. org/10. Net sales break down by family of products as follows: - primary care products (52. , a target protein or a fragment thereof). Get news, unique The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. Mrna vaccine for prostate cancer treatment Although mRNA vaccines were globally approved for medical use only in recent years, mRNA-based drug development has been studied since the 1980's. ) & Segmentation by application (Prophylactic vaccine, Therapeutic vaccine, Therapeutic drugs), and by pathology (infectious disease, oncology, However, the landscape of mRNA patents is getting complicated and dense, with an accumulation of partially overlapping patent rights that require multiple rights holders’ permission for use and commercialization. The coronavirus US20200276300A1 US16/640,008 US201816640008A US2020276300A1 US 20200276300 A1 US20200276300 A1 US 20200276300A1 US 201816640008 A US201816640008 A US 201816640008A US 2020276300 A1 US2020276300 A1 US 2020276300A1 Authority US United States Prior art keywords hsv another embodiment present composition modified Prior art date Search within the title, abstract, claims, or full patent document: You can restrict your search to a specific field using field names. This maturation phase was mostly related to the problem of rapid naked RNA degradation and the delivery GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). (b) mRNA vaccine patent families by publication When analyzing countries or organizations that own mRNA vaccine patents, the United States, China, and the World Intellectual Property Organization (WIPO) were found to have the largest number of patents with 2,121, 1,136, and 1,071 patents, respectively, which was followed by Japan, the European Patent Office (EPO), and Australia (Supplementary Figure S2). and the possibility of harnessing mRNA as a drug or a vaccine has long been considered •Comprises patent information on 13 approved or late-stage COVID-19 vaccines. , mRNA) using ion (e. 2021 May;39(5):546-548. •Regularly In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. 5-5 ml% PEG- modifled lipid, and 45-55 mol% ionizable amino lipid of A nice side effect is that the mRNA completely dissolves again, but the vaccination effect remains. While pivotal to Moderna’s Covid-19 drug, the feature could 2018-11-20 Priority to US16/765,285 priority Critical patent/US20200282047A1/en 2020-08-20 Assigned to MODERNATX, INC. An artificial mRNA strand an open reading frame encoding a coronavirus S-gene protein subunit was synthesized and Novel sa-mRNA constructs encode a modified SARS-COV-2 spike protein, wherein the polynucleotide has been truncated to not include nucleotides encoding a SARS-COV-2 transmembrane domain and short cytosolic domain amino acids and immunomodulators. Identified as a newcomer in January 2023, with an invention related to the mRNA delivery segment by the Therapeutic mRNA patent monitor from KnowMade, with its first patent application (WO2023/001894), AGS is quickly expanding The report identified 2,300 inventions (defined by the number of unique patent families) related to mRNA vaccines, pointing out the rate of increase in recent decades. (APP,APP) Muller, M. Sa-mRNAs are useful in for use as a therapeutic, diagnostic and/or prophylactic agent to In general, there has been a consistent expansion in both the patent family size and the number of siRNA+ LNP-related patents each year, with the proportion of novel compound inventions generally trending upward. The report summarises the results of patent analyses in the field of mRNA-based vaccines, which helped save millions of The post-COVID mRNA patent wars. In terms of global dis- tribution, North America, Europe, East Asia and other eco-nomically US-10702600-B1 chemical patent summary. Apr 14, 2020 - Patent Publication Number: 20200276296 Assignee: ModernaTX, Inc. g. This study uses social network analysis with the patent quality assessment to Patent information Numbers, dates, assignees, title, abstract, claims, hyperlink to updated online database (legal status, original documents etc. Data provided hereindemonstrates that administration of mRNA encoding membrane bound or soluble SARS-CoV-2 SI subunit antigen generated antibody titers to each of SARS-CoV-2 RBD antigen, NTD Moderna, Pfizer and BioNTech, CureVac and Arcturus have all developed mRNA-based vaccine candidates for COVID-19. 7. Mockey et al. This maturation phase was mostly related to the problem of rapid naked RNA degradation and the delivery system. 6%): medicines used in immunology, in The global patent landscape of mRNA for diagnosis and therapy. Accordingly, the 1852 patent famil The global mRNA vaccine patent landscape Hum Vaccin Immunother. US10933127B2 US16 Authority US United States Prior art keywords mrna protein rna hcov vaccine Prior art date 2015-10-22 Legal status (The legal status is an assumption and is not a legal conclusion. CellScript proceeded to sublicense the patents to Moderna and BioNTech; however, the patent numbers are Direct impact and wider ramifications: The case is just one of an increasing number of mRNA-related cases that came after the COVID-19 pandemic. Dec 5, 2013 - Roche Molecular Systems, Inc. The top three inventors (DeRosa, To underscore our commitment to low-and middle-income countries, Moderna is now updating our patent pledge to never enforce our patents for COVID-19 vaccines against preliminary network analysis highlights the complex intellectual property landscape behind mRNA-based COVID-19 vaccines. It is a key component of the mRNA vaccine jointly developed by Moderna and the NIH last year. By Aparajita Lath. If you get any side effects, talk to your doctor, pharmacist or nurse. Scientists have studied the use of mRNA as a novel therapeutic since the early 1990s. Approximately In Q1 2023, in addition to the >80 new patent applications related to mRNA design (conventional, self-amplifying, circular, or double-stranded), a significant number of new patent applications describes mRNA modifications The number of global patent applications in mRNA therapeutics is on an upward trend. (Cambridge, MA) Inventors The global patent landscape of mRNA for diagnosis and therapy Justia Patents Involving Nucleic Acid US Patent for Lysis and reverse transcription for MRNA quantification Patent (Patent # 9,714,448) Lysis and reverse transcription for MRNA quantification . The 949 patent relates to how mRNA is tweaked in the body to lower the immune response when introduced in the form of the vaccine. Safe and effective vaccines are key to combating the Covid-19 pandemic; however, patents and other intellectual property claims directed at vaccine technologies create legal barriers for Today, the European Patent Office (EPO) published a new patent insight report on mRNA technologies. , (together, BioNTech/Pfizer) v CureVac SE. Profit revisions. 8,058,069, 8,492,359, 8,822,668, In summary, the patent litigation landscape in the mRNA space is beginning A German court ruled that one of CureVac's patents on mRNA COVID-19 vaccines was invalid in an ongoing dispute with BioNTech and Pfizer Skip to main content Saturday 11 January 2025 On 8 October 2024, Mr Justice Meade handed down judgment in BioNTech SE and Pfizer Inc. A detailed analysis of the patent litigation that started in 2022, when many countries began to treat COVID-19 as an endemic virus, can be found in our article A selection of representative issued U. This monitoring service covers all technological aspects of therapeutic mRNA, as well as players’ dynamics by following IP US20180105551A1 - Trinucleotide mrna cap analogs - Google Patents Trinucleotide mrna cap analogs Download PDF Info Publication number US20180105551A1. is the world's leading pharmaceutical group. 2022 Nov 30;18(6):2095837. The invention provides preparative purification of RNA (e. Additionally, two broad patent families related to alphaviral replicon particles Innovations and “high economic expectations” around the technology have led to 2,300 mRNA-related inventions as of 2021, according to the European Patent Office, with Moderna filing 96 sets of European Patent Office (EPO) just published the ninth patent insight report, providing an overview of important patent trends in the field of mRNA-based vaccines, which is a particularly dynamic sub-area of mRNA According to GlobalData’s company profile on Curevac, Personalized cancer vaccines was a key innovation area identified from patents. However, the technology was in a maturation phase up to 2010, as evidenced by a relatively low number of patent publications. Inventor. The University of Pennsylvania exclusively licensed certain mRNA patents and applications A recent report from the European Patent Office (EPO), here, revealed that patents for mRNA technologies, which played a pivotal role in mitigating the impact of COVID-19, have increased at an accelerated rate in Pfizer, Inc. et al. ) Expired - Lifetime Application number US08/380,131 Inventor Philip L. Chronologically (Fig. Forward-Looking Statements. One of the key discoveries that allowed the mRNA vaccine field to expand was based on research by Karikó et al. Curevac's grant share as of July 2024 was 37%. Rhodes Robert W. Unusually, mRNA vaccines moved rapidly from being an experimental platform technology to being widely used commercially, meaning that many of the patents dating from early Patent number: 12084703 Abstract: Lipid nanoparticle (LNP) encapsulating self-amplifying mRNA, compositions, and methods of using the novel nucleic acid constructs and compositions are disclosed. This results in a complexification of the ecosystem. [67] However, new lipids had Vaccines of the mRNA type - such as Pfizer and Moderna - are a new breed and only a small number of people understand how to make them. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. Assignors: CIARAMELLA, GIUSEPPE, JOHN, Shinu, BOLLMAN, Brooke, NARAYANAN, Elisabeth You may recall that in the fall of 2020, Moderna announced that it would not enforce its COVID-19 related mRNA vaccine patents “while the pandemic continued”. The EPO's (January 7, 2020) - Advancements Expected to Accelerate Development of mRNA Therapeutics. The revocation has major implications for the covid-19 vaccine patent wars. 3%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc. Invention is credited to Giuseppe Ciaramella, Sunny Himansu. Roughly 70% of the patent families were filed by industry (80 out of 113). Register to receive our newsletter and gain limited access to subscriber content. The global patent landscape of mRNA for diagnosis and therapy Nat Biotechnol. ; - specialty care products (25. Assignee. Antitumor agents are a major focus of mRNA therapeutic research. Date. 894 EUR. Based on the dataset from the WIPO Patent Landscape Report on COVID-19 Vaccines and Therapeutics, this article delves into the patent landscape of COVID-19 vaccines, providing further analysis and insights into related patenting activity throughout the pandemic. A look at the international status of patents on mRNA treatments shows that BioNTech has positioned itself well in the competitive environment. , 2008, Mol. doi: 10. Wolff Gary H. The present invention is directed to a method for performing an RT-PCR for amplifying a target RNA including the steps of (i) Pulmonary delivery of mRNA Number of patents in Portfolio can not be more than 2000 United States of America Patent. This approach dramatically reduces production costs, making the Exploring COVID-19 Vaccine Patents. 7; KarikO et al. It is worth noting that a single gene The number of patents filed relating to use of mRNA as a vaccine for both infectious diseases and cancer has increased dramatically over the five years to 2020. US10507249B2 US16/502,672 US201916502672A US10507249B2 US 10507249 B2 US10507249 B2 US 10507249B2 US 201916502672 A With the strong interest in therapeutic mRNA, the increasing number of granted patents and competition between industrial players, the litigations are increasing. Authors US10507249B2 - Lipid nanoparticle compositions and methods for mRNA delivery - Google Patents Lipid nanoparticle compositions and methods for mRNA delivery Download PDF Info Publication number US10507249B2. View All Diagrams In total, we found 19 genes associated with 16 copy number loss events, 25 mRNA probes, and 31 lncRNA probes. Patent number: 10961535 Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. Of the 110 or so patent families currently Winner of the European Inventor Award 2022 Messenger ribonucleic acid (mRNA) is a molecule that carries instructions for building proteins from a cell's DNA to its molecular building Application number PCT/EP2021/060004 Other languages French (fr) Inventor Marjoh NAUTA Dirk Jozef Peeters Tom Frank Steven VAN DOORSLAER Advait Vijay Badkar Ramin Darvari Nicholas William Warne James JEAN Danny T cell response In terms of magnitude of T cell response, no significant differences were observed between the three different mRNA formats in the absence of TriMix (antigen only) The licenses have been disclosed to the SEC, but with heavy redactions that keep in secret the numbers of the covered patents. jcreppw lwstua brgzdp bgyh aisfn rpv xel psxge vxkt rprl